{"id":"NCT05456529","sponsor":"Incyte Corporation","briefTitle":"Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis","officialTitle":"A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages â‰¥ 12 Years to < 18 Years) With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-09-01","primaryCompletion":"2024-05-17","completion":"2024-05-17","firstPosted":"2022-07-13","resultsPosted":"2025-06-25","lastUpdate":"2025-06-25"},"enrollment":103,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis (AD)"],"interventions":[{"type":"DRUG","name":"Ruxolitinib Cream","otherNames":["INCB18424 cream"]}],"arms":[{"label":"Ruxolitinib","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"up to 462 days","effectByArm":[{"arm":"Ruxolitinib 1.5% Cream BID","deltaMin":42,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":18},"locations":{"siteCount":38,"countries":["United States","Canada","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":103},"commonTop":["Upper respiratory tract infection","Nasopharyngitis"]}}